Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Summary

This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.

Timeline

Start

2016-10

Primary completion

2017-11

Completion

2017-11

Outcome

Missed primary endpoint

registry RVT-101 35 mg vs Placebo; p = 0.3565; Mean Difference (Final Values) -1.90 (95% CI -6.04 to 2.23) NCT02910102 ↗

registry RVT-101 35 mg vs Placebo; p = 0.9220; Mean Difference (Final Values) -0.17 (95% CI -3.73 to 3.38) NCT02910102 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	intepirdine	Small molecule	35 mg	Oral

Indications